Compugen - CGEN Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last twelve months. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CGEN shares.
View CGEN analyst ratings or view top-rated stocks.

6 Wall Street research analysts have issued 12-month price targets for Compugen's shares. Their CGEN share price forecasts range from $2.00 to $13.00. On average, they expect the company's share price to reach $6.20 in the next twelve months. This suggests a possible upside of 783.2% from the stock's current price.
View analysts price targets for CGEN or view top-rated stocks among Wall Street analysts.

Compugen's stock was trading at $0.7157 at the beginning of the year. Since then, CGEN stock has decreased by 1.9% and is now trading at $0.7020.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.
View our CGEN earnings forecast.

Compugen Ltd. (NASDAQ:CGEN) issued its earnings results on Monday, February, 27th. The biotechnology company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.10. The biotechnology company had revenue of $7.50 million for the quarter. During the same period in the prior year, the company earned ($0.10) EPS.

2 employees have rated Compugen Chief Executive Officer Anat Cohen-Dayag on Glassdoor.com. Anat Cohen-Dayag has an approval rating of 100% among the company's employees. This puts Anat Cohen-Dayag in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Netflix (NFLX), Gilead Sciences (GILD) and Pfizer (PFE).

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CGEN stock can currently be purchased for approximately $0.70.

Compugen (NASDAQ:CGEN) has a market capitalization of $60.81 million and generates $7.50 million in revenue each year. The biotechnology company earns $-33,690,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

Compugen's mailing address is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. The official website for the company is www.cgen.com. The biotechnology company can be reached via phone at (723) 765-8585, via email at ir@cgen.com, or via fax at 972-3765-8555.